Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use ZENBEXUS safely and effectively. See full prescribing information for ZENBEXUS.ZENBEXUS™ (iberdomide) capsules, for oral useInitial U.S. Approval: 2026
Medication labelWhy this: Advisory · dailymed-prescription
ZENBEXUS is indicated, in combination with daratumumab and hyaluronidase-fihj and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least 1 prior line of therapy including a proteasome inhibitor and an immunomodulatory agent. This indication is approved under accelerated approval based on minimal residual disease (MRD)-negative complete response (CR) at any time [see Clinical Studies (14)]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
- generic_name
- iberdomide
- product_names
- iberdomide
- ndc
- 0003-5700, 0003-5700-21, 0003-5710, 0003-5710-21
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en